You are here
GENVEC, INC.
UEI: N/A
# of Employees: 15
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
In Vivo Editing for Hemophilia Gene Therapy
Amount: $430,170.00Project Summary The exceptional promise of gene therapy for hemophilia has been shown in recent studies that result in long term correction of factor IX deficiency via hepatic transduction with an a ...
STTRPhase I2017Department of Health and Human Services National Institutes of Health -
Adenovirus-vectored RSV vaccine not inhibited by maternal immunity
Amount: $589,058.00DESCRIPTION (provided by applicant): RSV is the leading viral cause of lower respiratory illness and hospitalization in young children, yet there isn't an approved vaccine. The vast majority of c ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Pre-erythrocytic Stage Antigen Discovery for Malaria Vaccine Development
Amount: $600,000.00DESCRIPTION (provided by applicant): The development of an effective malaria vaccine is a high global health priority. Malaria is the most burdensome parasitic disease of man, exacting an estimated to ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Development of an Ad14 Vaccine
Amount: $500,313.00DESCRIPTION (provided by applicant): Recent reports indicate that a new strain of adenovirus serotype 14 (Ad14) is causing frequent acute respiratory disease (ARD) and deaths in otherwise health peopl ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Development of Novel Alternative Serotype Adenoviral Vectors for Gene Delivery in
Amount: $138,699.00DESCRIPTION (provided by applicant): Myriad studies have examined the potential of gene therapy in the inner ear. For the most part they have focused on adenoviral vectors and delivery into the cochl ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Production of Adenovector Based Vaccines
Amount: $2,470,960.00DESCRIPTION (provided by applicant): Adenovirus vectors (Advectors) designed to express an antigenic gene have shown great promise as vaccines. Although GenVec and other groups have constructed numero ...
SBIRPhase II2009Department of Health and Human Services National Institutes of Health -
Local Therapy-A Novel Approach to Cancer Metastases
Amount: $295,991.00DESCRIPTION (provided by applicant): Metastases are the leading cause of death of most cancer patients. Leveraging the immune system to eliminate micrometastasis has long been attempted with only mode ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
High Throughput Genomics Screening for Malaria Antigen Discovery
Amount: $600,000.00DESCRIPTION (provided by applicant): Malaria is a major threat to world health. Each year, there are 350-500 million clinical cases and greater than one million deaths due to malaria, primarily of chi ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Preclinical Testing of an Adenoviral Vector based HSV-2 Vaccine
Amount: $600,000.00DESCRIPTION (provided by applicant): This proposal will leverage the expertise in HSV-2 and cellular immunology developed at the UW/FHCRC with the state of the art adenovirus delivery platform develop ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Adenovirus Vectors for Respiratory Syncytial Virus Vaccination
Amount: $600,000.00DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the leading viral cause of lower respiratory illness and hospitalization in young children and has long been recognized as a p ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health
